EY: We will see Danish IPOs, but…
The desired investor base and pricing are factors that determine a company’s choice of stock exchange, says the head of EY Life Science, who expects to see IPOs of Danish biotech companies this year. But there is a catch.
BY STEFAN SINGH KAILAY
There is a strong pipeline and even more innovative products on the way from Danish medtech and biotech companies, but nevertheless we see a lot less capital flowing into the sector compared with Scandinavian neighbor Sweden.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish pipeline is number one in Europe
For abonnenter
